Insulin Resistance

Insulin Resistance

Insulin resistance is a metabolic state in which the body’s cells, especially in skeletal muscle, the liver and fat tissue, respond less to insulin. Normally, insulin helps glucose move from the blood into cells, where it is used for energy or stored as glycogen. When cells become insulin resistant, more insulin is needed to get the same glucose-lowering effect, so the body makes extra (compensatory hyperinsulinemia). Over time, if the pancreatic beta cells cannot keep up this higher output, blood sugar rises, moving from prediabetes to full type 2 diabetes.

Insulin resistance is closely linked to excess visceral fat and is seen as a central driver of metabolic syndrome. Visceral fat releases inflammatory cytokines and free fatty acids that interfere with insulin signaling in other tissues. This sets up a vicious cycle: insulin resistance encourages more fat storage, especially around the abdomen, which makes insulin resistance worse. Breaking that cycle is a main goal of drugs for obesity and type 2 diabetes.

Retatrutide tackles insulin resistance in several complementary ways. Its GLP-1 and GIP receptor activity directly boosts insulin release and sensitivity, while its glucagon component increases fat burning in the liver and energy use, shrinking the visceral fat that drives insulin resistance. In Phase 2 trials, retatrutide significantly improved markers of insulin sensitivity alongside very large weight loss, which suggests the triple agonist approach may be especially good at reversing the metabolic problems linked to insulin resistance.